Oncorus Lands $57,000,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4f152cf1-1e2c-4b89-bab1-98e4a0cfa655 - Date
7/20/2016 - Company Name
Oncorus - Mailing Address
450 Kendall St. 4th Floor Cambridge, MA 02142 USA - Company Description
Oncorus, Inc. is an early-stage biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers. - Website
http://www.oncorus.com - Transaction Type
Venture Equity - Transaction Amount
$57,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds from the Series A financing round will be used to advance Oncorus’s immunotherapy platform using its next-generation oncolytic herpes simplex virus (oHSV). - M&A Terms
- Venture Investor
MPM Capital - Venture Investor
Deerfield Capital - Venture Investor
Celgene - Venture Investor
Undisclosed
